The Spartan DX-12™ DNA analyzer, developed and manufactured by Spartan Bioscience Inc is now available for world-wide commercial use.
Designed for non-batched PCR applications, the DX-12 is an easy-to-use, lightweight stand-alone instrument that produces both qualitative and quantitative results typically in 30-60 minutes.
"The commercial release of the Spartan DX-12 is the culmination of 3 1/2 years of intense development," said Mark Kershey, President, Spartan Bioscience. "We are pleased that the first clinical validation of the instrument was completed by the Children’s Hospital of Eastern Ontario (CHEO) and presented last month at the Clinical Virology Symposium in Florida and this validation has generated significant interest in our on-demand PCR analyzer. Our existing orders for the DX-12 will start shipping in June and the resellers that have been waiting for this device are being contacted to set the stage for global shipments."
Key operating features of the Spartan DX-12 include:
- 12-well sample capacity and dual-channel optical detection
- Performs 2 or 3 temperature PCR programs
- Small size means minimal bench footprint
- Fully stand-alone; no computer required to operate or interpret results
- Built-in Reverse Transcription (RT) program for RNA analysis
- Melt curve analysis
- Quantitative analysis
- Compatible with leading reagents and kits
Spartan will be showcasing the DX-12 at the BIO International Convention in Atlanta, GA, May 18-21, 2009, in the Province of Ontario Pavilion booth # 3311.
Spartan Bioscience Inc. is a privately-held molecular diagnostic instrumentation company developing, manufacturing, and marketing DNA analyzers for on-demand applications. Founded in 2005, the company focus is on applications where rapid and convenient DNA testing is particularly important, such as low-throughput research experiments or time-critical diagnostic testing for infectious diseases.
